vTv Therapeutics T1D KOL Breakfast
Please join vTv Therapeutics (VTVT) for a KOL breakfast highlighting the Type 1 Diabetes treatment landscape and emerging therapies as treatment adjuncts to insulin.
Date:
Tuesday, October 8th
Time:
8:00 AM EST Registration & Breakfast
8:30 AM: Presentations / Q&A
Location:
New York, NY
For more information or to RSVP, please email mbiega@troutgroup.com
General Agenda
Introduction
Steve Holcombe, President & CEO, vTv Therapeutics
T1D Overview and Treatment Landscape
Kevan C. Herold, MD, CNH, Professor of Immunobiology and Internal Medicine; Deputy Director, Yale Center for Clinical Investigation, Yale University
T1D Patient Perspective
Esther Latres, PhD, Director, Research, JDRF
Treatment Adjuncts to Insulin in T1D
John B. Buse, MD, PhD, Verne S. Caviness Distinguished Professor, Chief, Division of Endocrinology; Director, Diabetes Center; Director, NC Translational and Clinical Sciences Institute; Executive Associate Dean, Clinical Research, University of North Carolina School of Medicine
TTP399, a Liver Selective Glucokinase Activator, Ph2 Results and Recently Presented Data at the 55th Annual Meeting of the European Association for the Study of Diabetes
Carmen Valcarce, EVP & CSO, vTv Therapeutics
KOLs Perspective on TTP399 Data
Q&A
Closing Remarks
Steve Holcombe, President & CEO, vTv Therapeutics